Kathryn Rutland
Addiction Medicine · Louisville, KYNPI 1851586176
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 185 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by AbbVie at 29.1% of the total. Reporting peaked in 2021 at $812 and has fallen 97.6% since, to $19 in 2025.
Across 185 payments — averaging $15.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$829
- Otsuka America Pharmaceutical, Inc.$402
- Sunovion Pharmaceuticals Inc.$252
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$238
- Takeda Pharmaceuticals U.S.A., Inc.$175
- Alkermes, Inc.$144
- plus $812 from 16 others
What the payments were for
- Food & beverage$2,850100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 64 | $829 |
| Otsuka America Pharmaceutical, Inc. | 30 | $402 |
| Sunovion Pharmaceuticals Inc. | 11 | $252 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 13 | $238 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $175 |
| Alkermes, Inc. | 7 | $144 |
| Lundbeck LLC | 8 | $138 |
| Teva Pharmaceuticals USA, Inc. | 7 | $115 |
| Jazz Pharmaceuticals Inc. | 4 | $78 |
| Bausch Health US, LLC | 4 | $71 |
| Corium, LLC | 5 | $70 |
| Indivior Inc. | 3 | $58 |
| Ironshore Pharmaceuticals Inc. | 2 | $40 |
| Almatica Pharma LLC | 2 | $40 |
| Axsome Therapeutics, Inc. | 2 | $39 |
| Noven Therapeutics, LLC | 2 | $39 |
| Johnson & Johnson | 1 | $28 |
| Neurocrine Biosciences, Inc. | 1 | $27 |
| Tris Pharma Inc | 1 | $18 |
| Gilead | 1 | $18 |
| OWP Pharmaceuticals, Inc. | 1 | $17 |
| Alfasigma USA, Inc. | 1 | $17 |
How this compares
$2,850 in reported general payments places this provider in the 75th percentile of 40 addiction medicine providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 46 | $7,638 |
| Acamprosate Calcium | 13 | $2,771 |
| Buprenorphine Hcl | 11 | $541 |
| Gabapentin | 17 | $189 |
| Topiramate | 11 | $108 |
| Diazepam | 18 | $90 |
Paid to pharmacies, not to this prescriber.
Other addiction medicine in Louisville
- Asad IsmailLouisville$10K
- David AndersonLouisville$2K
- Richard CalesLouisville$1K
- Julia SchroederLouisville$695
- John StockingLouisville$534
- Stuart UrbachLouisville$124
- Allison KoetterLouisville$106
- Nanine HendersonLouisville$92
- Stephanie WaltonLouisville$60
- Irwin CohenLouisville$15
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.